Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $38
Analyst Ratings For EyePoint Pharmaceuticals
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals: Promising Growth Potential With Innovative Treatments and Strategic Leadership
Express News | EyePoint Pharmaceuticals Inc - Topline Data From Phase 3 Trials Expected in 2026
Express News | EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 Lugano Clinical Trial of Duravyutm for the Treatment of Wet Age-Related Macular Degeneration
Scotiabank Initiates Coverage On EyePoint Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $18
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
EyePoint Pharmaceuticals (EYPT) Receives a Buy From Mizuho Securities
Further Weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) Drops 12% This Week, Taking Five-year Losses to 54%
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Capital One Financial analyst Tim Chiang maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success
EyePoint Pharmaceuticals Announces Board Changes and New Appointments
Express News | EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Jefferies analyst Kambiz Yazdi initiates coverage on $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and sets the target price at $15.According to TipRanks data, the analyst has a success
Jefferies Initiates EyePoint Pharmaceuticals at Buy
Karen Zaderej Spends US$100k Buying EyePoint Pharmaceuticals Shares
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments